Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¾Æ½ºÇǸ° ¹× Ç×ÀÀ°íÁ¦ º¹¿ë ȯÀÚ¿¡¼­ ¼ÒÈ­¼º±Ë¾ç ÃâÇ÷ÀÇ Ä¡·á Management of Peptic Ulcer Bleeding in Patients Taking Aspirin or Anticoagulant

´ëÇѼÒÈ­±âÇÐȸÁö 2020³â 76±Ç 5È£ p.242 ~ 245
¾çÈ¿ÁØ,
¼Ò¼Ó »ó¼¼Á¤º¸
¾çÈ¿ÁØ ( Yang Hyo-Joon ) 
Sungkyunkwan University School of Medicine Kangbuk Samsung Hospital Department of Internal Medicine

Abstract


Antiplatelet and anticoagulation agents are increasingly prescribed for secondary prophylaxis in patients with cardiovascular and cerebrovascular diseases. These drugs are associated with an increased risk of gastrointestinal bleeding, including peptic ulcer bleeding. It is difficult to decide when to restart the agents after peptic ulcer bleeding in these patients because the risk of rebleeding and thromboembolism should be balanced. The Korean College of Helicobacter and Upper Gastrointestinal Research revised the guidelines for drug-induced peptic ulcers as evidence-based guidelines using a de novo process. This paper introduces new recommendations on the resumption of antiplatelet and anticoagulation agents after peptic ulcer bleeding based on the revised guidelines for drug-induced peptic ulcers.

Å°¿öµå

Peptic ulcer hemorrhage; Aspirin; Platelet aggregation inhibitors; Anticoagulants; Guideline

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

MEDLINE
KCI
KoreaMed
KAMS